EMA Withdrawn: Eperzan (albiglutide) — GlaxoSmithKline Trading Services Limited

View source ↗

Summary

The EMA has withdrawn Eperzan (albiglutide) from the European market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Eperzan (albiglutide)

Snippet

Status: Withdrawn. Therapeutic area: Diabetes Mellitus, Type 2. MAH: GlaxoSmithKline Trading Services Limited. Decision date: 14/09/2017